Mutational signatures in PDXs for improved understanding of drug response and companion biomarkers identification 

Genomic DNA editing, influenced by DNA repair mechanisms and external factors like carcinogens or therapies, plays a key role in cancer development. Recent analyses have identified mutational signatures that highlight DNA repair deficiencies or environmental exposures. This poster highlights our TumorGraft platform, which features 1,500 patient-derived xenografts from over 50 cancer types. Each model is molecularly characterized using transcriptomics, proteomics, and genomic variation, offering valuable insights into cancer biology and mutational signatures providing a comprehensive preclinical platform for evaluating new drugss

• PDXs (Patient-Derived Xenografts) retain mutational signatures that correlate with tumor etiology and clinical features of patients.

• PDXs were also effective in identifying new mutational signatures for model selection and biomarker discovery.

• Integrating mutational signature data into the PPMO workflow could significantly aid in identifying companion biomarkers and developing unique molecular profiles to enhance personalized medicine approaches.